Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Formulation exports boost Zydus Cadila's revenues in Q3

This article was originally published in Scrip

Executive Summary

Zydus Cadila has reported a 31% increase in revenues to Rs7.59 billion ($155.5 million) for the third quarter ended December 2008, led by a surge in formulations exports. Net profits rose by 17% to Rs610 million. The profits are after providing for an exchange rate fluctuation loss of Rs110 million on conversion of foreign currency loans during the quarter, as against a gain of Rs60 million during the same period last year. Formulation exports rose by 61%.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC031328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel